查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
治療性抗體的全球市場：型態、疾病領域、給藥途徑、最終用戶、區域、競爭形勢- 分析和預測（2024-2033）
市場調查報告書
商品編碼
1397516

治療性抗體的全球市場：型態、疾病領域、給藥途徑、最終用戶、區域、競爭形勢- 分析和預測（2024-2033）

Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 137 Pages | 商品交期: 1-5個工作天內

價格

全球抗體治療市場在生物製藥和生命科學領域中發揮著至關重要的作用，致力於用於醫療和研究領域多種應用的抗體的生產、改進和商業化。

這些抗體（免疫球蛋白）是免疫系統產生的必需蛋白質，對於識別和中和有害病原體、毒素和外來物至關重要。在市場上，抗體的生產、修飾和應用有多種目的，包括診斷、治療、研究、疾病檢測和治療、實驗室實驗和藥物開發。

全球抗體治療市場的擴張是由幾個影響因素所推動的。主要是，慢性病盛行率的不斷上升和對標靶治療的需求不斷增加正在推動對創新治療方法的探索。

該報告考察了全球治療性抗體市場，並提供了市場概況，包括型態、疾病領域、給藥途徑、最終用戶、地區以及進入市場的公司概況分類的趨勢。

目錄

執行摘要

第1章 市場

  • 趨勢：當前和未來的影響評估
  • 供應鏈概覽
  • 研究發展回顧
  • 監管狀況
  • 全球重大事件的影響分析 - COVID-19
  • 市場動態概覽

第2章 應用

  • 應用細分
  • 應用概述
  • 全球抗體治療市場（按疾病領域）
  • 全球抗體治療市場（依給藥途徑）
  • 全球抗體治療市場（按最終用戶）

第3章 產品

  • 產品細分
  • 產品概要
  • 全球抗體治療市場
  • 全球抗體治療市場（按型態）

第4章 區域

  • 區域概況
  • 促進因素和抑制因素
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第5章市場－競爭基準化分析與公司概況

  • 未來的主要企業
  • 地理評估
    • Hoffmann-La Roche Ltd.
    • AbbVie, Inc
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Regeneron Pharmaceuticals Inc.
    • Novartis AG
    • AstraZeneca
    • Eli Lilly and Company
    • GlaxoSmithKline plc.
    • Takeda Pharmaceutical Company Ltd.
    • Abcam Plc.
    • Thermo Fisher Scientific, Inc
    • Cell Signaling Technology

第6章調查方法

Product Code: BHL1660SA

“Global Antibody Therapeutic Market Poised for Remarkable Growth.”

The global antibody therapeutic market occupies a pivotal role within the biopharmaceutical and life sciences sectors, dedicated to the manufacturing, advancement, and commercialization of antibodies with diverse applications in medical and research domains. These antibodies, or immunoglobulins, are essential proteins generated by the immune system, crucial for identifying and neutralizing harmful pathogens, toxins, and foreign substances. Within the market context, antibodies are produced, modified, and applied for a spectrum of purposes, encompassing diagnostics, therapeutics, and research endeavors, spanning disease detection and treatment to laboratory experiments and pharmaceutical development.

The expansion of the global antibody therapeutic markets was propelled by several influential factors. Primarily, the rising prevalence of chronic diseases and the escalating demand for targeted therapies have intensified the quest for innovative treatment modalities.

Market Segmentation:

Segmentation 1: by Disease Area

  • Autoimmune and Inflammatory Disease
  • Oncology
  • Haematology
  • Infectious Disease
  • Osteology
  • Immunology
  • Neurology
  • Others Disease Area

Segmentation 2: by Route of Administration

  • Intravenous
  • Subcutaneous
  • Others Route of Administration

Segmentation 3: by End-User

  • Hospitals
  • Long term Care Facilities
  • Others End-User

Segmentation 4: by Format

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Antibody Fragments
  • Bispecific Antibodies
  • Others Novel Antibody Therapies

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

Key Questions Answered:

  • What are the growth opportunities for new entrants in the global antibody therapeutic sector?
  • Who are the primary players operating within the global antibody therapeutics market?
  • What key strategies are likely to be embraced by participants aiming to expand their share in the global antibody therapeutic industry?
  • How is the competitive landscape shaping up in the global antibody therapeutics market?
  • What emerging trends might impact the growth of the global antibody therapeutics market?
  • Which product type segment is anticipated to demonstrate a substantial CAGR in the future?
  • Which application segment is poised to capture a significant share in the global antibody therapeutic industry?
  • Which region presents lucrative opportunities for manufacturers in the global antibody therapeutics market?

Table of Contents

Executive Summary

1. Markets

  • 1.1. Trends: Current and Future Impact Assessment
    • 1.1.1. Sample Text
    • 1.1.2. Trend 1
    • 1.1.3. Trend 2
    • 1.1.4. Trend 3
  • 1.2. Supply chain Overview
    • 1.2.1. Value Chain Analysis
    • 1.2.2. Market Map
  • 1.3. Research and Development Review
    • 1.3.1. Patent Filing Trend (by Country, Company)
  • 1.4. Regulatory Landscape
  • 1.5. Impact Analysis for Key Global Events- COVID-19
  • 1.6. Market Dynamics Overview
    • 1.6.1. Market Drivers
    • 1.6.2. Market Restraints
    • 1.6.3. Market Opportunities

2. Application

  • 2.1. Application Segmentation
  • 2.2. Application Summary
  • 2.3. Global Antibody Therapeutic Market (By Disease Area)
    • 2.3.1. Autoimmune and Inflammatory Disease
    • 2.3.2. Oncology
    • 2.3.3. Haematology
    • 2.3.4. Infectious Disease
    • 2.3.5. Osteology
    • 2.3.6. Immunology
    • 2.3.7. Neurology
    • 2.3.8. Others Disease Area
  • 2.4. Global Antibody Therapeutic Market (By Route of Administration)
    • 2.4.1. Intravenous
    • 2.4.2. Subcutaneous
    • 2.4.3. Others Route of Administration
  • 2.5. Global Antibody Therapeutic Market (By End-User)
    • 2.5.1. Hospitals
    • 2.5.2. Long term Care Facilities
    • 2.5.3. Others End-User

3. Products

  • 3.1. Product Segmentation
  • 3.2. Product Summary
  • 3.3. Global Antibody Therapeutic Market
    • 3.3.1. Market Overview
      • 3.3.1.1. Analyst View
  • 3.4. Global Antibody Therapeutic Market (By Format)
    • 3.4.1. Monoclonal Antibodies
    • 3.4.2. Polyclonal Antibodies
    • 3.4.3. Antibody Fragments
    • 3.4.4. Bispecific Antibodies
    • 3.4.5. Others Novel Antibody Therapies

4. Regions

  • 4.1. Regional Summary
  • 4.2. Drivers and Restraints
  • 4.3. North America
    • 4.3.1. Regional Overview
    • 4.3.2. Driving Factors for Market Growth
    • 4.3.3. Factors Challenging the Market
    • 4.3.4. Application
    • 4.3.5. Product
    • 4.3.6. U.S.
    • 4.3.7. U.S. Antibody Therapeutic Market by Application
    • 4.3.8. Canada
    • 4.3.9. Canada Antibody Therapeutic Market by Application
  • 4.4. Europe
    • 4.4.1. Regional Overview
    • 4.4.2. Driving Factors for Market Growth
    • 4.4.3. Factors Challenging the Market
    • 4.4.4. Application
    • 4.4.5. Product
    • 4.4.6. Germany
    • 4.4.7. Germany Antibody Therapeutic Market by Application
    • 4.4.8. U.K.
    • 4.4.9. U.K. Antibody Therapeutic Market by Application
    • 4.4.10. France
    • 4.4.11. France Antibody Therapeutic Market by Application
    • 4.4.12. Rest of Europe
    • 4.4.13. Rest of Europe Antibody Therapeutic Market by Application
  • 4.5. Asia Pacific
    • 4.5.1. Regional Overview
    • 4.5.2. Driving Factors for Market Growth
    • 4.5.3. Factors Challenging the Market
    • 4.5.4. Application
    • 4.5.5. Product
    • 4.5.6. China
    • 4.5.7. China Antibody Therapeutic Market by Application
    • 4.5.8. Japan
    • 4.5.9. Japan Antibody Therapeutic Market by Application
    • 4.5.10. India
    • 4.5.11. India Antibody Therapeutic Market by Application
    • 4.5.12. Rest-of-Asia-Pacific
    • 4.5.13. Rest-of-Asia-Pacific Antibody Therapeutic Market by Application
  • 4.6. Rest-of-the-World (RoW)
    • 4.6.1. Regional Overview
    • 4.6.2. Driving Factors for Market Growth
    • 4.6.3. Factors Challenging the Market
    • 4.6.4. Application
    • 4.6.5. Product
    • 4.6.6. Latin America
    • 4.6.7. Latin America Antibody Therapeutic Market by Application
    • 4.6.8. The Middle East and Africa
    • 4.6.9. The Middle East and Africa Antibody Therapeutic Market by Application

5. Markets - Competitive Benchmarking & Company Profiles

  • 5.1. Next Frontiers…..
  • 5.2. Geographic Assessment
    • 5.2.1. Hoffmann-La Roche Ltd.
      • 5.2.1.1. Overview
      • 5.2.1.2. Top Products / Product Portfolio
      • 5.2.1.3. Top Competitors
      • 5.2.1.4. Target Customers
      • 5.2.1.5. Key Personnel
      • 5.2.1.6. Analyst View
      • 5.2.1.7. Market Share
    • 5.2.2. AbbVie, Inc
      • 5.2.2.1. Overview
      • 5.2.2.2. Top Products / Product Portfolio
      • 5.2.2.3. Top Competitors
      • 5.2.2.4. Target Customers
      • 5.2.2.5. Key Personnel
      • 5.2.2.6. Analyst View
      • 5.2.2.7. Market Share
    • 5.2.3. Amgen Inc.
      • 5.2.3.1. Overview
      • 5.2.3.2. Top Products / Product Portfolio
      • 5.2.3.3. Top Competitors
      • 5.2.3.4. Target Customers
      • 5.2.3.5. Key Personnel
      • 5.2.3.6. Analyst View
      • 5.2.3.7. Market Share
    • 5.2.4. Bristol-Myers Squibb Company
      • 5.2.4.1. Overview
      • 5.2.4.2. Top Products / Product Portfolio
      • 5.2.4.3. Top Competitors
      • 5.2.4.4. Target Customers
      • 5.2.4.5. Key Personnel
      • 5.2.4.6. Analyst View
      • 5.2.4.7. Market Share
    • 5.2.5. Johnson & Johnson Services, Inc.
      • 5.2.5.1. Overview
      • 5.2.5.2. Top Products / Product Portfolio
      • 5.2.5.3. Top Competitors
      • 5.2.5.4. Target Customers
      • 5.2.5.5. Key Personnel
      • 5.2.5.6. Analyst View
      • 5.2.5.7. Market Share
    • 5.2.6. Merck & Co., Inc.
      • 5.2.6.1. Overview
      • 5.2.6.2. Top Products / Product Portfolio
      • 5.2.6.3. Top Competitors
      • 5.2.6.4. Target Customers
      • 5.2.6.5. Key Personnel
      • 5.2.6.6. Analyst View
      • 5.2.6.7. Market Share
    • 5.2.7. Regeneron Pharmaceuticals Inc.
      • 5.2.7.1. Overview
      • 5.2.7.2. Top Products / Product Portfolio
      • 5.2.7.3. Top Competitors
      • 5.2.7.4. Target Customers
      • 5.2.7.5. Key Personnel
      • 5.2.7.6. Analyst View
      • 5.2.7.7. Market Share
    • 5.2.8. Novartis AG
      • 5.2.8.1. Overview
      • 5.2.8.2. Top Products / Product Portfolio
      • 5.2.8.3. Top Competitors
      • 5.2.8.4. Target Customers
      • 5.2.8.5. Key Personnel
      • 5.2.8.6. Analyst View
      • 5.2.8.7. Market Share
    • 5.2.9. AstraZeneca
      • 5.2.9.1. Overview
      • 5.2.9.2. Top Products / Product Portfolio
      • 5.2.9.3. Top Competitors
      • 5.2.9.4. Target Customers
      • 5.2.9.5. Key Personnel
      • 5.2.9.6. Analyst View
      • 5.2.9.7. Market Share
    • 5.2.10. Eli Lilly and Company
      • 5.2.10.1. Overview
      • 5.2.10.2. Top Products / Product Portfolio
      • 5.2.10.3. Top Competitors
      • 5.2.10.4. Target Customers
      • 5.2.10.5. Key Personnel
      • 5.2.10.6. Analyst View
      • 5.2.10.7. Market Share
    • 5.2.11. GlaxoSmithKline plc.
      • 5.2.11.1. Overview
      • 5.2.11.2. Top Products / Product Portfolio
      • 5.2.11.3. Top Competitors
      • 5.2.11.4. Target Customers
      • 5.2.11.5. Key Personnel
      • 5.2.11.6. Analyst View
      • 5.2.11.7. Market Share
    • 5.2.12. Takeda Pharmaceutical Company Ltd.
      • 5.2.12.1. Overview
      • 5.2.12.2. Top Products / Product Portfolio
      • 5.2.12.3. Top Competitors
      • 5.2.12.4. Target Customers
      • 5.2.12.5. Key Personnel
      • 5.2.12.6. Analyst View
      • 5.2.12.7. Market Share
    • 5.2.13. Abcam Plc.
      • 5.2.13.1. Overview
      • 5.2.13.2. Top Products / Product Portfolio
      • 5.2.13.3. Top Competitors
      • 5.2.13.4. Target Customers
      • 5.2.13.5. Key Personnel
      • 5.2.13.6. Analyst View
      • 5.2.13.7. Market Share
    • 5.2.14. Thermo Fisher Scientific, Inc
      • 5.2.14.1. Overview
      • 5.2.14.2. Top Products / Product Portfolio
      • 5.2.14.3. Top Competitors
      • 5.2.14.4. Target Customers
      • 5.2.14.5. Key Personnel
      • 5.2.14.6. Analyst View
      • 5.2.14.7. Market Share
    • 5.2.15. Cell Signaling Technology
      • 5.2.15.1. Overview
      • 5.2.15.2. Top Products / Product Portfolio
      • 5.2.15.3. Top Competitors
      • 5.2.15.4. Target Customers
      • 5.2.15.5. Key Personnel
      • 5.2.15.6. Analyst View
      • 5.2.15.7. Market Share

6. Research Methodology

  • 6.1. Data Sources
    • 6.1.1. Primary Data Sources
    • 6.1.2. Secondary Data Sources
    • 6.1.3. Data Triangulation
  • 6.2. Market Estimation and Forecast

List of Figures

  • Figure 1: Global Antibody Therapeutic Market, by region, 2022, 2026, and 2033
  • Figure 2: Pricing/Cost Analysis by Region, Supply Chain
  • Figure 3: Global Antibody Therapeutic Market, by Format, 2022, 2026, and 2033
  • Figure 4: Global Antibody Therapeutic Market, by Disease Area, 2022, 2026, and 2033
  • Figure 5: Global Antibody Therapeutic Market, by Route of Administration, 2022, 2026, and 2033
  • Figure 6: Global Antibody Therapeutic Market, by End User, 2022, 2026, and 2033
  • Figure 7: Global Antibody Therapeutic Market, Recent Developments
  • Figure 8: Supply chain and Identifying Risks within the Supply Chain
  • Figure 9: Global Antibody Therapeutic Market, 2022, 2026, and 2023
  • Figure 10: Global Antibody Therapeutic Market, 2022, 2026, and 2026
  • Figure 11: Impact Analysis of Market Navigating Factors
  • Figure 12: U.S. Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 13: U.S. Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 14: Canada Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 15: Canada Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 16: Germany Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 17: Germany Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 18: U.K. Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 19: U.K. Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 20: France Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 21: France Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 22: Rest of Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 23: Rest of Europe Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 24: China Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 25: China Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 26: Japan Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 27: Japan Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 28: India Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 29: India Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 30: Rest-of-Asia-Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 31: Rest-of-Asia-Pacific Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 32: Latin America Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 33: Latin America Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 34: The Middle East and Africa Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 35: The Middle East and Africa Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 36: Strategic Initiatives, 2020 - 2023
  • Figure 37: Share of Strategic Initiatives
  • Figure 38: Data Triangulation
  • Figure 39: Top-Down and Bottom-Up Approach
  • Figure 40: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Antibody Therapeutic Market, Opportunity
  • Table 3: Global Antibody Therapeutic Market, by Product, $Million, 2022-2033
  • Table 4: Antibody Therapeutic Market, By Region, ($ Million), 2022-2033
  • Table 5: North America Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 6: North America Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 7: North America Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 8: U.S. Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 9: U.S. Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 10: Canada Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 11: Canada Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 12: Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 13: Europe Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 14: Europe Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 15: Germany Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 16: Germany Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 17: U.K. Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 18: U.K. Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 19: France Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 20: France Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 21: Rest of Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 22: Rest of Europe Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 23: Asia Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 24: Asia Pacific Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 25: Asia Pacific Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 26: China Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 27: China Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 28: Japan Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 29: Japan Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 30: India Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 31: India Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 32: India Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 33: Rest-of-Asia-Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 34: Rest-of-Asia-Pacific Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 35: Rest-of-the-World Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 36: Rest-of-the-World Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 37: Rest-of-the-World Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 38: Latin America Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 39: Latin America Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 40: The Middle East and Africa Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 41: The Middle East and Africa Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 42: Market Share